19.90
0.00
(0.00%)
As of April 3 at 4:00:00 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jan 1970) | Next Qtr. (Jan 1970) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jan 1970) | Next Qtr. (Jan 1970) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 3 | 4 |
| Avg. Estimate | -- | -- | 6.2B | 7.01B |
| Low Estimate | -- | -- | 6.18B | 6.92B |
| High Estimate | -- | -- | 6.22B | 7.17B |
| Year Ago Sales | -- | -- | 5.54B | 6.2B |
| Sales Growth (year/est) | -- | -- | 12.00% | 13.11% |
EPS Trend
| Currency in USD | Current Qtr. (Jan 1970) | Next Qtr. (Jan 1970) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jan 1970) | Next Qtr. (Jan 1970) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AKBLF | -- | -- | -- | -- |
| S&P 500 | 6.68% | 6.74% | 9.91% | 14.34% |
Related Tickers
AKESF Akeso, Inc.
10.62
0.00%
ZEAL.CO Zealand Pharma A/S
426.20
-7.99%
GUBRA.CO Gubra A/S
373.00
-10.34%
ROIV Roivant Sciences Ltd.
9.60
-4.15%
BAVA.CO Bavarian Nordic A/S
143.15
-5.23%
IMVT Immunovant, Inc.
14.37
-8.94%
GMAB.CO Genmab A/S
1,251.50
-2.61%
ARWR Arrowhead Pharmaceuticals, Inc.
10.93
-9.37%
NVAX Novavax, Inc.
6.02
+7.50%
RXRX Recursion Pharmaceuticals, Inc.
4.2650
-11.33%